Clinical Trial Finder
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Study Purpose
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Recruitment Criteria
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Key
Inclusion Criteria:
- - Are able to swallow capsules twice daily.
KeyExclusion Criteria:
Trial Details
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
The main questions this clinical trial aims to answer are:
- - may continue dosing, if safe to do so, until not effective or other decision to stop is
made.
- participate in multiple visits that include additional evaluations, laboratory tests and diary review until after stopping the investigational drugArms
Experimental: MBQ-167 oral capsule
A dose ranging from 10mg to 400mg BID following a standard 3+3 cohort design
Interventions
Drug: - MBQ-167
MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
International Sites
Status
Recruiting
Address
FDI Clinical Research
San Juan, , 00927
Site Contact
Mirelis Acosta-Rivera, MD
[email protected]
(787) 722-1248
Privacy Overview